Levetiracetam Actavis

New Zealand - English - Medsafe (Medicines Safety Authority)

Active ingredient:
Levetiracetam 500 mg;  
Available from:
Teva Pharma (New Zealand) Limited
INN (International Name):
Levetiracetam 500 mg
Dosage:
500 mg
Pharmaceutical form:
Film coated tablet
Composition:
Active: Levetiracetam 500 mg   Excipient: Colloidal silicon dioxide Crospovidone Magnesium stearate Opadry yellow 85F32371 Povidone
Prescription type:
Prescription
Manufactured by:
Neuland Laboratories Limited
Therapeutic indications:
Use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. Monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. Add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (IGE).
Product summary:
Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with LDPE screw cap and tamper evident - 100 tablets - 36 months from date of manufacture stored at or below 25°C
Authorization number:
TT50-9702a
Authorization date:
2015-01-22

Similar products

Search alerts related to this product

Share this information